Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Depreciation Expense (2016 - 2019)

Amicus Therapeutics filings provide 6 years of Depreciation Expense readings, the most recent being $991000.0 for Q1 2019.

  • On a quarterly basis, Depreciation Expense rose 2.27% to $991000.0 in Q1 2019 year-over-year; TTM through Mar 2019 was $4.2 million, a 12.71% increase, with the full-year FY2025 number at $3.9 million, down 22.0% from a year prior.
  • Depreciation Expense hit $991000.0 in Q1 2019 for Amicus Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Depreciation Expense ranged from a high of $1.2 million in Q4 2018 to a low of $353000.0 in Q2 2015.
  • Median Depreciation Expense over the past 5 years was $873500.0 (2016), compared with a mean of $830562.5.
  • Biggest five-year swings in Depreciation Expense: fell 10.86% in 2015 and later soared 126.84% in 2016.
  • Amicus Therapeutics' Depreciation Expense stood at $395000.0 in 2015, then skyrocketed by 129.37% to $906000.0 in 2016, then increased by 22.96% to $1.1 million in 2017, then grew by 6.37% to $1.2 million in 2018, then dropped by 16.37% to $991000.0 in 2019.
  • The last three reported values for Depreciation Expense were $991000.0 (Q1 2019), $1.2 million (Q4 2018), and $1.1 million (Q3 2018) per Business Quant data.